Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
Abstract | BACKGROUND: METHODS: This 52-week, phase 2/3, randomized, double-blind study evaluated adalimumab for induction and maintenance treatment in 273 anti-TNF-naive Japanese patients with UC who were refractory to corticosteroids, immunomodulators, or both. Patients received placebo, adalimumab 80/40 (80 mg at week 0, then 40 mg every other week), or adalimumab 160/80 (160/80 mg at weeks 0/2, then 40 mg every other week) in addition to background UC therapy. RESULTS: At week 8, remission rates were similar among treatment arms, but more patients treated with adalimumab 160/80 achieved response (placebo, 35 %; 80/40, 43 %; 160/80, 50 %; P = 0.044 for 160/80 vs placebo) and mucosal healing (placebo, 30 %; 80/40, 39 %; 160/80, 44 %; P = 0.045 for 160/80 vs placebo) compared with placebo. At week 52, more patients receiving adalimumab 40 mg every other week achieved response (18 vs 31 %; P = 0.021), remission (7 vs 23 %; P = 0.001), and mucosal healing (16 vs 29 %; P = 0.015) compared with placebo. Week 8 response to adalimumab was associated with greater rates of response (61 %), remission (46 %), and mucosal healing (57 %) at week 52 relative to the overall population. Rates of serious adverse events were similar between treatment arms. CONCLUSIONS: Induction with adalimumab 160/80 mg led to early response and mucosal healing. Maintenance adalimumab had greater rates of long-term response, remission, and mucosal healing compared with placebo. No new safety signals were identified.
|
Authors | Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Takayuki Matsumoto, Toshifumi Hibi, Anne M Robinson, Nael M Mostafa, Jingdong Chao, Vipin Arora, Anne Camez, Roopal B Thakkar, Mamoru Watanabe |
Journal | Journal of gastroenterology
(J Gastroenterol)
Vol. 49
Issue 2
Pg. 283-94
(Feb 2014)
ISSN: 1435-5922 [Electronic] Japan |
PMID | 24363029
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Antibodies, Monoclonal, Humanized
- Immunosuppressive Agents
- Adalimumab
|
Topics |
- Adalimumab
- Adrenal Cortex Hormones
- Adult
- Anti-Inflammatory Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Antibodies, Monoclonal, Humanized
(adverse effects, pharmacokinetics, therapeutic use)
- Colitis, Ulcerative
(drug therapy)
- Double-Blind Method
- Drug Resistance
- Female
- Humans
- Immunosuppressive Agents
- Japan
- Maintenance Chemotherapy
- Male
- Middle Aged
- Remission Induction
- Severity of Illness Index
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|